13:30-14:20 [Plenary Lecture 1] National Cancer Plans: The French experience Chairperson: Kiyohiko Hatake (Department of Hematology, International University of Health and Welfare, School of Medicine/ Cancer Chemotherapy Center, Japanese Foundation for Cancer Research)
PL1
National Cancer Plans: The French experience .......................................................................................................20 David Khayat Medical Oncology Department, Clinique BIZET
14:30-16:30
[Symposium 1] Recent progress in genitourinary cancers
Chairpersons: David Khayat  (Medical Oncology Department, Clinique BIZET) Takeshi Yuasa (Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research) S1-1 Recent development in surgical and systemic therapy for renal cell carcinoma …………………………………24 Tsunenori Kondo Tokyo Women's Medical University Medical Center East S1-2 Recent advances in medical therapy for metastatic GU malignancy......................................................24 Takeshi Yuasa Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research S1-3 An overview of medical treatment in urothelial cancers.............................................................................25 Chihiro Kondoh Toranomon Hospital, Department of Medical Oncology
16:30-18:30
[Symposium 4] Molecular biology of lymphoma and novel therapies (Joint Symposium of Anti-Cancer Treatment Japan & The 22nd Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer) Chairpersons: Mamiko Sakata-Yanagimoto (Department of Hematology, University of Tsukuba) Takeshi Takahashi (Kyowa Hakko Kirin Co., Ltd.) S4-1 Recent advances in therapeutics for B-cell lymphoma.............................................................................30 Yasuhito Terui'.² ' Department of Hematology Oncology, Cancer Institute Hospital of JFCR ² Division of Clinical Chemotherapy, Cancer Chemotherapy Center of JFCR S4-2 Microenvironment and immunity of peripheral T-cell lymphoma including AILT and ATLL ........30 Koichi Ohshima Department of Pathology, School of Medicine, Kurume University S4-3 Development and molecular analysis of synthetic lethality by targeting EZH1 and EZH2 in malignant lymphomas . Makoto Yamagishi Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo S4-4 Immunotherapy of Lymphoma Ranjana Hira Advani Stanford Cancer Institute
14:30-16:30 [Symposium 2  ] Lung cancer : new treatment for ALK/Ros pathways Chairpersons: Makoto Maemondo (Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine) Naoko Aragane (Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University) S2-1 Clinical advance in ALK/ROS1 treatment .............................................................................................................26 Yasushi Goto National Cancer Center S2-2 Pathological features and diagnosis of ALK-, ROS1- and RET-rearranged lung cancer .................26 Yuchi Ishikawa, Kengo Takeuchi Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo S2-3 Discovery research of ALK inhibitor alectinib..................................................................................................27 Hiroshi Sakamoto Research Division, Chugai Pharmaceutical Co., Ltd. S2-4 Resistance mechanisms to ALK/ROS1 tyrosine kinase inhibitors in n non-small cell lung cancer ..27 Eiji Iwama Department of Comprehensive Clinical Oncology, Kyushu University, Fukuoka, Japan
16:30-18:30
[Symposium 5] Advances in gastrointestinal cases : gastie&CRC Chairpersons: Yasushi Tsujii (Department of Medical Oncology Tonan Hospital) Takayuki Yoshino (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) S5-1 Practical management of metastatic colorectal cancer ...............................................................................32 Yasushi Tsuji Department of Medical Oncology, Tonan Hospital S5-2 S5-3 Current standard of chemotherapy for advanced gastric cancer in Japan..........................................32 Daisuke Takahari Department of Gastroenterology, Cancer Institute Hospital of Japan Foundation for Cancer Research Activity on Nationwide Cancer Genome Screening Project for Metastatic Colorectal Cancer in Japan; SCRUM-Japan GI-SCREEN Takayuki Yoshino Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan S5-4 Combinations with immune-oncology agents for GI cancers ..........................................................................33 Kohei Shitara National Cancer Center Hospital East

14:30-16:30
[Symposium 3] Genome medicine and sarcoma treatment Chairpersons: Shunji Takahashi (Department of Medical Oncology, Cancer Institute Hospital, JFCR, Tokyo, Japan) Katsuhito Takahashi (International University of Health and Welfare, Mita Hospital Sarcoma Center) S3-1 Practical management of rare and complicated solid tumors: cancer of unknown primary (CUP) and soft tissue sarcoma (STS) . Kenji Nakano The Department of Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan S3-2 Treatment for advanced soft tissue sarcoma: importance of multidisciplinary approach and clinical trials Shunji Takahashi Department of Medical Oncology, Cancer Institute Hospital, JFCR, Tokyo, Japan The Cutting Edge of Sarcoma Genomics ...............................................................................................................29 Katsuhito Takahashi Sarcoma Center, Medical Oncol. & Genomics, International Univ. of Health and Welfare, Tokyo, Japan S3-3 S3-4 Fusion genes in sarcoma and mouse models Miwa Tanaka, Takuro Nakamura Division of Carcinogenesis, Cancer institute, Japanese foundation for cancer research
16:30-18:30
[Symposium 6] Biomarker CTC, and circulating DNA Chairpersons:Satoshi Matsusaka (Department of Clinical Research and Regional Innovation, University of Tsukuba, Tsukuba, Japan) Yuji Mishima (Japanese Foundation for Cancer Research) S6-1 Clinical relevance of circulating tumor cells in metastatic colorectal cancer patients .................34 Satoshi Matsusaka Department of Clinical Research and Regional Innovation, University of Tsukuba, Tsukuba, Japan S6-2 Basic approach in CTC and FISH in single cell  ................................................................................................................34 Yuji Mishima', Yasuhito Terui', Kiyohiko Hatake',2 ¹ Japanese Foundation for Cancer Research ² International University of Health and Welfare, Mita Hospital S6-3 S6-4 Circulating tumor DNA and tumor progression .............................................................................................35 Naoko Aragane Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University Circulating tumour cell analysis to predict efficacy of Eribulin for patients with metastatic breast cancer … Yoshiya Horimoto Department of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan S6-5 Circulating Tumor Cells (CTCs): Detection and clinical significance in thoracic malignancies. .....36 Kazue Yoneda Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health, Kitakyushu, Japan Friday, May 18  Room4

9:00-11:00
[Symposium 7] Biomarker positive breast cancer Chairpersons: David Khayat  (Medical Oncology Department, Clinique BIZET) Kiyohiko Hatake (Department of Hematology, International University of Health and Welfare, School of Medicine/ Cancer Chemotherapy Center, Japanese Foundation for Cancer Research) S7-1 Development and current role of cdk 4/6 inhibitors in breast cancer … Gabriel N. Hortobagyi Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Infiltrating Lobular Carcinoma S7-2 Sandra M. Swain Research Development, Georgetown University Medical Center S7-3 Biomarkers in Oncology and Breast Cancer Edith A. Perez ¹,² ¹ BioOncology US Medical Affairs, Genentech, Inc. ² Mayo Clinic S7-4 The History of Breast Cancer Management in Japan .................................................................................38 Keiichiro Tada Department of Breast Surgery, National Center for Global Health and Medicine
11:00-11:50
[Plenary Lecture 2] Progress in managing hormone receptor-positive metastatic breast cancer Chairperson: David Khayat  (Medical Oncology Department, Clinique BIZET) PL2 Progress in managing hormone receptor-positive metastatic breast cancer ............................................2 Gabriel N. Hortobagyi Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
12:00-12:50
[Luncheon Seminar 1] Chairperson: Yasuhito Terui (Hematology Oncology Division, The Cancer Institute Hospital of JFCR) LS1 PTCL: What's new? Ranjana Hira Advani Stanford Cancer Institute Sponsored by Takeda Pharmaceutical Company Limited. 13:00-13:50 [Plenary Lecture 3] The path to success for HER2 positive advanced breast cancer Chairperson: Gabriel N. Hortobagyi  (Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center) PL3 The path to success for HER2 positive advanced breast cancer .............................................................23 Sandra M. Swain Research Development, Georgetown University Medical Center
14:00-17:00
[Symposium 12] Management of breast cancer survivors, Metastatic or advanced breast cancers
Chairpersons: Sandra M. Swain  (Research Development, Georgetown University Medical Center) Kiyohiko Hatake (Department of Hematology, International University of Health and Welfare, School of Medicine/ Cancer Chemotherapy Center, Japanese Foundation for Cancer Research) S12-1　CDK 4/6 inhibitors in Breast Cancer Sandra M. Swain Research Development, Georgetown University Medical Center S12-2 Management of Breast Cancer Survivors ...........................................................................................................47 Edith A. Perez ¹,² ¹ BioOncology US Medical Affairs, Genentech, Inc. ² Mayo Clinic S12-3   Current Management of Bone Metastases in Breast Cancer ....................................................................48 Gabriel N. Hortobagyi Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center S12-4   Clinical management of hereditary breast and ovarian cancer syndrome in Japan ......................48 Masami Arai Diagnostics and Therapeutics of Intractable Diseases, Juntendo University, Tokyo, Japan S12-5   The retrospective analysis of tumor shrinkage patterns during NAC in locally advanced low- grade luminal breast cancer . Ippei Fukada', Yoshinori Ito', Kokoro Kobayashi', Shibayama Tomoko', Naoya Gomi', Yumi Kokubu², Katsunori Oikado², Rie Horii³, Futoshi Akiyama², Shinji Ohno² 1 Department of Breast Medical Oncology, Breast Oncology Center, Cancer Institute Hospital of JFCR ² Department of Diagnostic Imaging, Cancer Institute Hospital of JFCR ² Department of Pathology, Cancer Institute Hospital of JFCR 4 Department of Pathology, Cancer Institute of JFCR ² Breast Oncology Center, Cancer Institute Hospital of JFCR
S12-6
Eribulin mesylate may improve the sensitivity of endocrine therapy in metastatic breast cancer Kokoro Kobayashi¹, Yoshinori Ito¹, Shinji Ohno² ¹ Department of Breast Medical Oncology, Cancer Institute Hospital of JFCR ² Breast Oncology Center, Cancer Institute Hospital of JFCR

9:00-11:00
[Symposium 8] Immune monitoring and adverse event management in immune check point inhibition Chairpersons: Shingo Yano (Division of Clinical Oncology and Hematology Department of Internal Medicine Jikei University School of Medicine) Hiroyoshi Nishikawa (Division of Cancer Immunology, Research Institute/EPOC, National Cancer Center, Tokyo/Chiba, Japan)
S8-1
Immune monitoring of immune suppressive network in tumor microenvironment Hiroyoshi Nishikawa¹ ⁄ ² ¹ Division of Cancer Immunology, Research Institute/EPOC, National Cancer Center, Tokyo/Chiba, Japan ² Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan S8-2 Mechanisms and managements of adverse events induced by immune checkpoint inhibitors in pituitary and thyroid glands Shintaro Iwama', Hiroshi Arima² ¹ Department of Endocrinology and Diabetes, Nagoya University Hospital, Nagoya, Japan ² Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine S8-3 Immune checkpoint inhibitors and neuromuscular adverse events … Shigeaki Suzuki Department of Neurology, Keio University School of Medicine S8-4 Immune Monitoring of Immunotherapy Trials: Considerations for Optimizing Yield of Informative Data .....................................................................................................................................................40 Phillip Wong Memorial Sloan Kettering Cancer Center
12:00-12:50
[Luncheon Seminar 2] Chairperson: Kiyohiko Hatake (Department of Hematology, International University of Health and Welfare, Mita Hospital) LS2 The Management of follicular lymphoma Dai Maruyama Department of Hematology, National Cancer Center Sponsored by Eisai Co., Ltd.
13:00-15:00
[Symposium 10] Myeloma and leukemia recent progress: MRD, Can we stop the treatment? Chairpersons: Tomoiku Takaku (Department of Hematology, Juntendo University School of Medicine) Yasuhito Terui (Department of Hematology Oncology, Cancer Institute Hospital of JFCR / Division of Clinical Chemotherapy, Cancer Chemotherapy Center of JFCR) S10-1 ABL tyrosine kinase inhibitor and minimal residual disease negativity during treatment and stop… Shinya Kimura Division of Hematology, Respiratory Medicine and Oncology, Saga University, Saga, Japan S10-2 MRD eradication by antibody containing treatment for myeloma ........................................................43 Tadao Ishida Department of Hematology, Japanese Red Cross Medical Center S10-3 Induction therapy for the treatment of newly diagnosed multiple myeloma ....................................44 Noriko Nishimura The Cancer Institute Hospital of JFCR S10-4   The impact of MYC translocation for the prognosis of follicular and relapse and refractory diffuse large B cell lymphoma . Yuko Mishima', Noriko Nishimura', Masahiro Yokoyama', Kiyohiko Hatake², Yasuhito Terui' ' Div. of Hematology, Oncology, The Cancer Institute Hospital, JFCR ² Dept of Hematology, International University of Health and Welfare,Mita Hospital.
15:00-17:00
[Symposium 13] Treatment for lung cancers: EGFR pathway and resistance analysis
Chairpersons: Masahiro Tsuboi (Department of Thoracic Surgery & Oncology, National Cancer Center Hospital East) Ryohei Katayama (Div. of Experimental Chemother., Cancer Chemother. Ctr., Japanese Foundation for Cancer Research) S13-1 EGFR inhibitor treatment for NSCLC in clinical practice .................................................................................50 Masahiro Tsuboi Department of Thoracic Surgery & Oncology, National Cancer Center Hospital East S13-2   Overcoming resistnace of EGFR-TKI . Makoto Maemondo Division of Respiratory Medicine, Allergy, and Rheumatology  Iwate Medical University S13-3   Liquid biopsy and re-biopsy for identification of mechanisms of acquired resistance to molecular targeted therapy Naoko Aragane Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University S13-4   EGFR-TKI resistance mechanisms and strategies to overcome the resistance using experimental models Ryohei Katayama', Ken Uchibori¹² Div. of Experimental Chemother., Cancer Chemother. Ctr., Japanese Foundation for Cancer Research ² Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research
9:00-11:00
[Symposium 9] Recent progress in gynecological cancers Chairpersons: Katsutoshi Oda (Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan) Ryo Konno (Jichi medical University Saitama Medical Center) S9-1 Molecular target therapy for uterine corpus tumors .....................................................................................41 Masashi Takano Department of Clinical Oncology, National Defense Medical College Hospital S9-2 Experience of immune checkpoint inhibitors in gynecological cancer..................................................41 Kohei Omatsu Gynecological Oncology, the Cancer Institute Hospital S9-3 Clinical sequencing in gynecologic cancer by Todai OncoPanel .................................................................42 Katsutoshi Oda', Michihiro Tanikawa', Kumiko Oseto', Shinji Kohsaka² 4 , Kawata Yoshiko', Kazunori Nagasaka ¹³, Yoko Matsumoto', Masaomi Nangaku ʻ , Kiyoshi Miyagawa ʻ , Hiroyuki Aburatani ⁵ , Hiroyuki Mano²⁴, Yutaka Osuga', Tomoyuki Fujii' 1 Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan ² National Cancer Center ² Department of Obstetrics and Gynecology, Teikyo University 4 Graduate School of Medicine, The University of Tokyo s RCAST, The University of Tokyo S9-4 Treatment for rucurrent or persistent cervical cancer and ovarian cancer ........................................42 Satoshi Takekuchi', Tadahiro Shoji', Masahiro Kagabu', Takayuki Nagasawa', Yukari Nitta', Hiroaki Itamochi¹, Yusuke Nakamura².³ 1 Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan ² Laboratory of Molecular Medicine, Human Genome Center Institute of Medical Science, University of Tokyo, Tokyo, Japan, ² The Chicago University, Chicago, IL,USA
12:00-12:50
[Luncheon Seminar 3] Chairperson: Shinya Kimura (Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Saga University)
LS3
Large Granular Lymphocytosis: A New Frontier in Immunological Functions for Hematological Malignancies Kazuki Taoka Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo Sponsored by Bristol-Myers Squibb
13:00-15:00
[Symposium 11] Treatment for pancreatic and biliary, hepatic cancers Chairpersons: Takashi Sasaki (Department of Gastroenterology,Cancer Institute Hospital of JFCR) Yasushi Tsuji (Department of Medical Oncology Tonan Hospital) S11-1 The current management and future perspective for advanced pancreatic cancer ....................45 Masato Ozaka Cancer Institute Hospital, Tokyo, Japan S11-2 Adjuvant chemotherapy for pancreatic and biliary cancer, current practice and future directions.  Yasushi Tsuji Department of Medical Oncology, Tonan Hospital S11-3 Recent advances in systemic chemotherapy for hepatocellular carcinoma ..........................................46 Masafumi Ikeda Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East S11-4 Downsizing Chemotherapy followed by Aggressive Surgical Resection for Advanced Biliary Tract Cancer Atsushi Kato', Masayuki Ohtsuka², Hideyuki Yoshitomi², Katsunori Furukawa², Tsukasa Takayashiki², Satoshi Kuboki², Makoto Takahashi', Satoshi Kadomura', Takashi Hatori', Yoshifumi Ikeda', Masaru Miyazaki¹ ' Digestive Diseases Center, International University of Health and Welfare, Mita Hospital, Japan ² Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Japan